Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 2, 2021 at 9:42 AM.

  1. #1 cafead, Sep 2, 2021 at 9:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Anti-CD25 antibodies have emerged as one of the most promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.

    article source
     
    Quote

Reply to Thread